As federal courts weigh the future of mifepristone access, some clinicians are preparing for a scenario many hoped was behind them: relying on misoprostol-only regimens for both abortion and early pregnancy loss care.
A recent ruling from the U.S. Court of Appeals for the Fifth Circuit would reinstate in-person dispensing requirements for mifepristone, which would curtail telehealth prescribing and mail distribution. The U.S. Supreme Court has temporarily paused those restrictions, but a final decision is still pending, leaving providers planning for multiple scenarios.
“At Planned Parenthood, we’ve actually been preparing for this moment for some time,” said Colleen McNicholas, DO, chief clinical transformation officer at Planned Parenthood Great Northwest, Hawai‘i, Alaska, Indiana, Kentucky. “We knew that mifepristone was going to be a target.”
If restrictions take effect, many providers would shift toward misoprostol-only protocols, which are supported by global evidence but differ in efficacy, dosing, and side effect profiles, said Eve Espey, MD, MPH, distinguished professor in the Department of Obstetrics and Gynecology at the University of New Mexico.
“The misoprostol-only regimen is a safe and effective alternative to the combination of mifepristone and misoprostol for medication management of early abortion and miscarriage,” Espey said.
Espey said the primary differences are “effectiveness and side effects.” While safe and effective, she said, misoprostol-only regimens are less effective and less predictable than the combined regimen, resulting in higher rates of ongoing pregnancy and more prolonged or irregular bleeding in some patients.
Indeed, McNicholas said that the combined regimen has efficacy “somewhere around 95%,” while misoprostol alone is “about 85%-95% effective,” depending on gestational age and regimen adherence.
Misoprostol-only regimens also require repeated dosing over a shorter interval and may increase the need for patient counseling around timing, expectations, and symptom management.
“The timing is a little bit different,” McNicholas said, adding that patients take multiple doses within hours rather than spacing medications over 24 to 48 hours.
According to Espey, because patients generally require more doses of misoprostol than in the combined regimen, clinicians should expect increased rates of nausea, chills, diarrhea, and temperature elevation, as well as potentially more unscheduled clinic or emergency department visits related to bleeding concerns or side effects.
Expanded Implications for Pregnancy Loss
The implications extend beyond abortion care. Because the same medications are used in miscarriage management, any restriction on mifepristone could have broader clinical consequences.
“Abortion doesn’t happen in a silo,” McNicholas said. “It is one pregnancy outcome of many, and we do use these medications routinely for other aspects of pregnancy care, most commonly for miscarriage management.”
She warned that challenges to the drug’s safety or availability could spill over into those settings.
“Attacking the sort of safety or the efficacy of the medication used in the indication of abortion absolutely will spill over into miscarriage management,” she said.
The Supreme Court’s temporary administrative stay preserving telehealth prescribing and mail distribution of mifepristone has been extended to May 14.
Even if the Court issues a longer-term stay, clinicians and health systems are likely to continue contingency planning as the broader legal challenge proceeds through the courts. And regardless of the outcome, maintaining clarity on the safety and effectiveness of abortion care is critical, McNicholas said.
“Any time abortion is in the media, people get confused,” McNicholas said. “Medication abortion by mail will still be available, it will still be safe. It might just look a little bit different.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.